Anti-Epidermal Growth Factor Receptor (EGFR) MoAbs, cetuximab and panitumumab, are currently administered in all-RAS (KRAS and NRAS) wild type (WT) mCRC patients as first or subsequent lines of treatment either in monotherapy or in association with chemotherapy, KRAS and NRAS tumor mutations being negative predictive biomarkers for their use. Here, EGFR is linked to neoplasm.